Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Annemiek Broijl; Marie-José Kersten; Wendimagegn Ghidey Alemayehu; Mark-David Levin; Okke de Weerdt; Edo Vellenga; Ellen Meijer; Shulamit Wittebol; Bea C. Tanis; Petra B. Cornelisse; Marian Stevens-Kroef; Gerard M. J. Bos; Pierre W. Wijermans; Henk Lokhorst; Pieter Sonneveld

doi:https://doi.org/10.3324/haematol.2015.132431

Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

Annemiek Broijl, Marie-José Kersten, Wendimagegn Ghidey Alemayehu, Mark-David Levin, Okke de Weerdt, Edo Vellenga, Ellen Meijer, Shulamit Wittebol, Bea C. Tanis, Petra B. Cornelisse, Marian Stevens-Kroef, Gerard M. J. Bos, Pierre W. Wijermans, Henk Lokhorst, Pieter Sonneveld

Research output: Contribution to journal › Comment/Letter to the editor › Academic

4 Citations (Scopus)

Original language	English
Pages (from-to)	e149-e152
Journal	Haematologica
Volume	101
Issue number	4
DOIs	https://doi.org/10.3324/haematol.2015.132431
Publication status	Published - Apr 2016

Keywords

VRD
escalated dose
first relapse
multiple myeloma

Access to Document

https://doi.org/10.3324/haematol.2015.132431

Cite this

Broijl, A., Kersten, M.-J., Alemayehu, W. G., Levin, M.-D., de Weerdt, O., Vellenga, E., Meijer, E., Wittebol, S., Tanis, B. C., Cornelisse, P. B., Stevens-Kroef, M., Bos, G. M. J., Wijermans, P. W., Lokhorst, H., & Sonneveld, P. (2016). Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma. Haematologica, 101(4), e149-e152. https://doi.org/10.3324/haematol.2015.132431

@article{9700e8c7b3f943fd977f467bee236644,

title = "Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma",

keywords = "VRD, escalated dose, first relapse, multiple myeloma",

author = "Annemiek Broijl and Marie-Jos{\'e} Kersten and Alemayehu, {Wendimagegn Ghidey} and Mark-David Levin and {de Weerdt}, Okke and Edo Vellenga and Ellen Meijer and Shulamit Wittebol and Tanis, {Bea C.} and Cornelisse, {Petra B.} and Marian Stevens-Kroef and Bos, {Gerard M. J.} and Wijermans, {Pierre W.} and Henk Lokhorst and Pieter Sonneveld",

year = "2016",

month = apr,

doi = "https://doi.org/10.3324/haematol.2015.132431",

language = "English",

volume = "101",

pages = "e149--e152",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "4",

}

Broijl, A, Kersten, M-J, Alemayehu, WG, Levin, M-D, de Weerdt, O, Vellenga, E, Meijer, E, Wittebol, S, Tanis, BC, Cornelisse, PB, Stevens-Kroef, M, Bos, GMJ, Wijermans, PW, Lokhorst, H & Sonneveld, P 2016, 'Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma', Haematologica, vol. 101, no. 4, pp. e149-e152. https://doi.org/10.3324/haematol.2015.132431

TY - JOUR

T1 - Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma

AU - Broijl, Annemiek

AU - Kersten, Marie-José

AU - Alemayehu, Wendimagegn Ghidey

AU - Levin, Mark-David

AU - de Weerdt, Okke

AU - Vellenga, Edo

AU - Meijer, Ellen

AU - Wittebol, Shulamit

AU - Tanis, Bea C.

AU - Cornelisse, Petra B.

AU - Stevens-Kroef, Marian

AU - Bos, Gerard M. J.

AU - Wijermans, Pierre W.

AU - Lokhorst, Henk

AU - Sonneveld, Pieter

PY - 2016/4

Y1 - 2016/4

KW - VRD

KW - escalated dose

KW - first relapse

KW - multiple myeloma

U2 - https://doi.org/10.3324/haematol.2015.132431

DO - https://doi.org/10.3324/haematol.2015.132431

M3 - Comment/Letter to the editor

C2 - 26659914

SN - 0390-6078

VL - 101

SP - e149-e152

JO - Haematologica

JF - Haematologica

IS - 4

ER -